3M (MMM)

As of 15 October 2026, short interest in MMM is 10,033,780 shares, up 49,445 shares over the last month. Over the last 48 readings it ranged from 6,029,083 shares (13 December 2024) to 11,728,170 shares (15 June 2026). At the reported average volume of 2.7M shares a day that is 3.7 days to cover.

<iframe src="https://xoomar.com/embed/stocks/mmm" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

As of 2 November 2026, the short share of MMM volume is 66.4%, up 7.7 points over the last five sessions. Over the last 30 readings it ranged from 41.0% (23 September 2026) to 73.6% (28 September 2026). The latest reading is 10.8 points above the 30-session average of 55.6%, on 1.1M shares reported.

As of 9 October 2026, the fails-to-deliver balance in MMM is 9,027 shares, up 8,873 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (4 June 2026) to 12,203 shares (3 August 2026).

Insiders at MMM reported 1 open-market sell worth $663K in the last 90 days and no open-market buys. Latest filing: Van Wyck Jonathan G. (EVP Chief Strategy Officer) on 2026-10-30.

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

15 Form 144 notices on file for MMM worth $23.8M at the prices reported; 1 in the last 90 days worth $663K. Latest: Chavez Rodriguez Beatriz Karina filed on 2026-08-05 to sell 3,635 shares ($663K) from 2026-08-05.

3 holders report 5% or more of MMM in their latest filing, all on Schedule 13G (passive). The largest reported stake is JPMORGAN CHASE & CO. at 8.5% of the class (44,111,814 shares), filed 2026-10-16 for an event on 2026-09-30.

9 of the 30 tracked managers held MMM at their latest 13F, $1.70B in total at quarter-end prices. D. E. Shaw & Co. is the largest at $788.7M (0.4% of its portfolio) as of 2026-06-30. Over the prior quarter 5 added shares and 4 cut.

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

In Q3 FY 2026 (quarter ended 2026-09-30) 3M reported revenue of $6.58B, up 1.0% from the same quarter a year earlier, and net income of $1.37B (2.63 diluted EPS). In FY 2025 it generated $2.31B of operating cash flow and spent $3.25B on buybacks and $1.56B on dividends.

Quarterly, last 8 quarters

Fiscal years, with buybacks and dividends

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-09-30; shares outstanding as of 2026-09-30 from the cover page.

4 contract actions on file for MMM: $186K obligated in the last 90 days and $814K in the last 12 months across 3 awarding agencies. The largest was $628K from the Department of Health and Human Services on 2026-07-30 (nih ongoing operational need for 3m papr units to support laboratories and offices to sustain mission critical activitie...). This covers the largest contract actions, not every award, and agencies report late.